These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24277958)

  • 1. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.
    Ambroszkiewicz J; Sands D; Gajewska J; Chelchowska M; Laskowska-Klita T
    Adv Med Sci; 2013; 58(2):338-43. PubMed ID: 24277958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Assessment of selected bone metabolism marker concentrations in children with cystic fibrosis].
    Ambroszkiewicz J; Gajewska J; Sands D; Chełchowska M; Ołtarzewski M; Laskowska-Klita T
    Med Wieku Rozwoj; 2012; 16(2):117-23. PubMed ID: 22971655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
    Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentrations of sclerostin and bone turnover markers in children with cow's milk allergy.
    Ambroszkiewicz J; Rowicka G; Chełchowska M; Gajewska J; Strucińska M; Laskowska-Klita T
    Med Wieku Rozwoj; 2013; 17(3):246-52. PubMed ID: 24296448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Tsigris C; Kostaki MA; Perrea DN
    J Endocrinol Invest; 2007 Oct; 30(9):762-6. PubMed ID: 17993768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Concentration of osteoprotegerin, bone formation and resorption markers in patients with phenylketonuria].
    Ambroszkiewicz J; Gajewska J; Chełchowska M; Ołtarzewski M; Laskowska-Klita T; Nowacka M; Milanowski A
    Pol Merkur Lekarski; 2008 Jul; 25(145):57-60. PubMed ID: 18839616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease.
    Siomou E; Challa A; Printza N; Giapros V; Petropoulou F; Mitsioni A; Papachristou F; Stefanidis CJ
    Pediatr Nephrol; 2011 Jul; 26(7):1105-14. PubMed ID: 21479768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents.
    Mora S; Zamproni I; Cafarelli L; Giacomet V; Erba P; Zuccotti G; Viganò A
    AIDS; 2007 May; 21(9):1129-35. PubMed ID: 17502723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineral-bone metabolism markers in young hemodialysis patients.
    Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
    Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
    Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
    Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
    Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls.
    Greer RM; Buntain HM; Potter JM; Wainwright CE; Wong JC; O'Rourke PK; Francis PW; Bell SC; Batch JA
    Osteoporos Int; 2003 Jun; 14(5):404-11. PubMed ID: 12730764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
    Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
    Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.
    Jacot W; Pouderoux S; Thezenas S; Chapelle A; Bleuse JP; Romieu G; Lamy PJ
    Breast Cancer Res Treat; 2012 Jul; 134(2):709-17. PubMed ID: 22562178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.